Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$110.03 USD
-3.15 (-2.78%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $110.02 -0.01 (-0.01%) 7:40 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.03 USD
-3.15 (-2.78%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $110.02 -0.01 (-0.01%) 7:40 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Zacks News
3 Stocks to Buy as Recession Looks Unlikely
by Sejuti Banerjea
These are opportunities to buy at reasonable valuations.
Jazz Pharmaceuticals (JAZZ) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.
What's in the Cards for Universal Health (UHS) in Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.
Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.
Will High Tech Costs Hurt Teladoc Health (TDOC) in Q2 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 results are likely to have benefited from improved access fees and growing BetterHelp membership, partly offset by elevated technology and development expenses.
Elevance Health (ELV) Beats on Q2 Earnings, Ups '23 Profit View
by Zacks Equity Research
Elevance Health's (ELV) Q2 results benefit from an expanding customer base and solid pharmacy product revenues. Adjusted net income is expected to be more than $32.85 per share for 2023.
Wall Street Analysts Think Jazz (JAZZ) Could Surge 54.74%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Jazz (JAZZ) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Uncover Value Opportunities With These 5 Earnings Yield Gems
by Rimmi Singhi
Unlock hidden value and drive higher returns to your portfolio with high earnings yield stocks like PLAY, URBN, KELYA, LTHM and JAZZ.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View
by Zacks Equity Research
Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.
Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -7.28% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 0% and 23.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Avalo Therapeutics, Inc. (AVTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 12.37% and 52.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.